1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
| {
| "batch_id": "BATCH-STOCK-VALUATION-QINGFENGPU-TIMELINE-20260825-001",
| "ticker": "002437.SZ",
| "company": "誉衡药业",
| "as_of": "2026-08-25",
| "v2_status": "BLOCKED",
| "v2_failure": {
| "complete": false,
| "error": "ValueError: E_HISTORICAL_SHARES_UNPROVEN：quote f124 缺失或为 0",
| "error_code": "E_CORE_INPUT",
| "error_type": "CoreInputError",
| "recorded_at": "2026-08-25T19:56:53.481+08:00",
| "rollback_errors": [],
| "run_id": "0236f4b427f1466e93f52370de6cbaf6",
| "schema_version": 2,
| "status": "BLOCKED"
| },
| "v2_runtime_package": "v2_002437_SZ.failed-0236f4b427f1466e93f52370de6cbaf6",
| "v2_raw_artifact_hashes": [
| "2b322852db4af764a98de112e074b86ae8213f8923a09457a8ebc59c0b1d0d0a",
| "4a53630f8dc012f8563b82f8500f01e76c90f5784300753189f2785b403da362",
| "58b0bf3190d738cf47628664e74bd8e908229a161c9b372aa4dedf22098eb42b",
| "5aacae90df805b85e41cd1b9f5e08a328c74f1baec0ca8fc1ab2820a7a430e39",
| "5f2da81c7274f70590926b6354d88789f0d04f6577d7c6b538c7032f1c80098e",
| "a02b976e06f4e4d6d4e1526a3085c830769a17fea2bbd665d08170014a1d11c0",
| "be3b60cc0768dd1e0cf7c8c3f341b7654ec463453ad15b2f4f18c56a410acb6e",
| "d2467a9eca03d93ed00897a3edd60e6c09f8f4f9997f867b0d3e3e95b263d2b9",
| "ea6528a2204b61a7ee34683a73ca00f8afdc86aadf3f765d4dae39bbfb19dbe7",
| "ef0a6fc85960d1b6c3d5dea2f7579178c807a7d278ded18d851dcca92c145b60"
| ],
| "market_contract": {
| "table": "trading_xuntou.cn_stock_kline_1d_front",
| "source": "xtquant",
| "source_batch_id": "FKL_20260825_161021_6bd1f63d_1d_20260825_00004",
| "updated_at": "2026-08-25 16:36:49",
| "trade_date": "2026-08-25"
| },
| "quote_raw_hash": "5aacae90df805b85e41cd1b9f5e08a328c74f1baec0ca8fc1ab2820a7a430e39",
| "share_proof": {
| "shares": 2229868126.0,
| "shares_fallback": false,
| "shares_fallback_source": "eastmoney.market:f84",
| "report_shares": 2229868126.0,
| "share_unit_correction": null,
| "static_total_shares": 2232028126.0,
| "match_report": true,
| "quote_market_cap": 9588432941.8,
| "price_times_shares": 9588432941.8,
| "gap_rate": 0.0
| },
| "industry_membership": {
| "industries": [
| "医药"
| ],
| "layers": [
| "reverse:医药、创新药与疫苗",
| "timeline"
| ],
| "research_name": "誉衡药业"
| },
| "bounded_gaps": [
| "V2 quote f124=0，端到端流程诚实阻断；正式估值用当前总股本/市值勾稽，股本历史日期无A1完全匹配时显式保留缺口。",
| "机构汇总缺逐家报告日期与明细，不把一致预期写成法定事实。"
| ],
| "checks": {
| "v1_qa": {
| "error_count": 0,
| "info_count": 1,
| "issues": [
| {
| "action": "补充法定披露、行情接口或机构预测汇总页来源。",
| "field": "institutions",
| "issue_id": "QA-CORE-SOURCE-MISSING",
| "message": "核心字段没有由注册表中允许承载核心数字的来源支持。",
| "recalc_scope": "institutions",
| "severity": "WARNING"
| },
| {
| "action": "不得以公司业绩预告或自有情景冒充机构预期。",
| "field": "institutions",
| "issue_id": "QA-INSTITUTION-NONE",
| "message": "估值日没有可用机构盈利预测，已明确记录为空。",
| "recalc_scope": "机构预期模块",
| "severity": "INFO"
| }
| ],
| "status": "PASS_WITH_WARNINGS",
| "warning_count": 1
| },
| "label": "偏贵",
| "base_low": 1.4570504793887529,
| "base_high": 3.57120215536459,
| "optimistic_high": 6.899562564164387,
| "price": 4.3,
| "bubble_status": "泡沫-中"
| }
| }
|
|
